

AVAILABLE FOR SALE IN THE USA AS EUA FOR BOTH SOFIA 2 AND SOFIA INSTRUMENTS

Objective SARS-CoV-2 Results at Your Fingertips



Accurate, objective and automated results in 15 minutes



Track via secure, remote instrument management with Virena®



Excellent performance compared to molecular methods

Flexible, dual mode testing for high

throughput in variety of laboratory

environments




Integrated data management automatically stores test and user history



User and patient ID captured with onboard barcode scanner



Sofia SARS Antigen FIA – Procedures



Sofia Development Modes



Sofia SARS Antigen FIA*

- Nasal and nasopharyngeal specimens
- Accurate detection with direct and VTM samples
- Results in 15 minutes
- Kit includes 25 sterile nasal swabs and a set of positive and negative control swabs
- Room temperature storage

*Refer to the Package Insert.



Sofia SARS Antigen FIA Clinical Performance

Nasopharyngeal in VTM		SARS-CoV-2 Molecular					95% CI	
		POS	NEG	Total	PPA	80%	68%	88%
Sofia SARS Antigen FIA	POS	47	0	47	NPA	100%	96%	100%
	NEG	12	84	96	PPV	100%	92%	100%
	Total	59	84	143	NPV	88%	79%	93%
					Prevalence	41%	34%	49%
					% agreement	92%		

Direct Nasal Swab	-	ra® SA JA2000	95% CI					
		POS	NEG	Total	Sensitivity	93.8%	71.7%	98.9%
Sofia SARS	POS	15	0	15	Specificity	100.0%	98.1%	100.0%
Antigen FIA	NEG	1	200	201	PPV	100.0%	79.6%	100.0%
	Total	16	200	216	NPV	99.5%	97.2%	99.9%
					Prevalence	7.4%	4.6%	11.7%
					% agreement	99.5%		



SL3202 | SS2037403EN00 (06/20)